Immunocore Holdings plc is a commercial-stage biotechnology company developing immunomodulating medicines for cancer, infectious diseases, and autoimmune diseases. The company operates the proprietary ImmTAX platform, which engineers soluble T cell receptor (TCR) bispecific therapeutics to modulate immune responses. Its lead product, KIMMTRAK (tebentafusp), is approved for the treatment of unresectable or metastatic uveal melanoma and is commercially launched in multiple territories, including the United States, Germany, and France. The pipeline includes brenetafusp for advanced cutaneous melanoma and ovarian cancer, IMC-R117C for solid tumors, and IMC-M113V for HIV. The company utilizes a hybrid commercialization model with an in-house sales force in the United States and partners such as Medison Pharma Ltd. and Er-Kim Pharmaceuticals for distribution in other regions. Manufacturing facilities are located in Denmark and Germany, with final packaging in the Netherlands. Immunocore has established partnerships with Genentech, GSK, and the Bill & Melinda Gates Foundation.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage immunocore.com
Sector Healthcare IR page immunocore.com/investors
Tags
t-cell receptor therapy, bispecific antibodies, uveal melanoma, cutaneous melanoma, hiv, autoimmune diseases, oncology, infectious diseases, immunotherapy, KIMMTRAK, tebentafusp, ImmTAX, brenetafusp, IMC-R117C, IMC-P115C, IMC-M113V, IMC-S118AI, IMC-U120AI, Medison Pharma Ltd., Er-Kim Pharmaceuticals Bulgaria EOOD
Press page immunocore.com/investors/news/press-releases

Metrics

Valuation  
Market cap $ 1.564B
Market cap (USD) $ 1.564B
P/E -45.89
PEG —
P/BV 3.73
P/S 3.64
P/OCF -150.22
P/FCF -85.91
Dividend yield —
Turnover / mcap —
Returns  
ROE -9.6%
ROI -4.6%
ROIC -4.4%
Profit margin -8.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 103.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 52
Quality score -29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 400.016M 310.202M 238.735M 169.023M 36.551M 38.894M 31.64M
Net profit -35.514M -51.087M -55.287M -48.476M -181.273M -95.695M -128.109M
Free cash flow -15.052M 20.888M -2.485M -32.547M -133.854M -82.205M -129.986M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 34.71 29.5 68.32 57.07 34.24 — —
Price performance 12m 0.18 -0.57 0.2 0.67 — — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 33.6M 52.1M 63M —
↳ YoY growth +55.1% +21.0%
Lease liabilities (USD) — — — — 33.6M 36M 41.7M 43.6M
Cash and deposits (USD) — — 177M 321M 402M 443M 456M 468M
Right-of-use assets (USD) — — — — 30.9M 33.5M 37.6M 38.8M
Cash flow detail
Operating cash flow (USD) — — — -143M -49.2M 2.94M 26.1M -10.7M
Purchases of property, plant and equipment (USD) — — — -1.39M -2.2M -5.43M -5.17M -4.34M
Change in receivables (cash effect) (USD) — — — -4.86M -26.3M -17.9M -12.3M -7.34M
Change in payables (cash effect) (USD) — — — 1.47M 4.91M 2.63M 7.27M -2.46M
Income taxes paid (cash effect) (USD) — — — -17M 765,000 977,000 -510,000 -4.64M
Share-based compensation (USD) — — — 48.9M 32.9M 32.5M 34.2M 37.7M
Operating cash flow before change in receivables (USD) — — — -138M -22.9M 20.8M 38.4M -3.38M
Free cash flow (OCF - PPE - intangibles) (USD) — — — -144M -51.4M -2.49M 20.9M -15.1M
Income detail
Research and development expense (GBP) 83.6M 100M 74.8M 73.2M 89.2M 164M 222M 275M
Total comprehensive income (USD) — — — -180M -76.9M -36.9M -48.6M -29.8M
Comprehensive income to owners (USD) — — — -180M -76.9M -36.9M -48.6M -29.8M
Reported Mar 25, 2021 Mar 25, 2021 Feb 28, 2024 Feb 28, 2024 Feb 28, 2024 Feb 28, 2024 Feb 26, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

KIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date

Phase 3 TEBE-AM trial for previously treated advanced cutaneous melanoma completed target enrollment of 540 patients – Topline overall survival data expected second quarter of 2027

Promising Phase 1 data with KIMMTRAK plus brenetafusp to be presented as a late-breaking oral at SITC - Randomized Phase 2/3 DUET-UVEAL trial planned

First person with type 1 diabetes dosed in the Phase 1 trial of IMC-S118AI, the Company’s first tissue-specific autoimmune candidate

Cash, cash equivalents and marketable securities of $901 million as of September 30, 2026

(OXFORDSHIRE, England & RADNOR, PA.

October 29, 2026 9:00am EDT Download as PDF

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK**®** (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

Clinical data for first combination of two T cell engagers in a solid tumor will be presented in a poster on Friday, November 6, and an oral presentation on November 7

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, October 29, 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present data from its Phase 1/2 trial evaluating brenetafusp alone and in combination with KIMMTRAK in HLA-A*02:01-positive patients with metastatic uveal melanoma, in a poster and oral session at the 2026 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

The poster and oral presentations will include additional safety and efficacy data. The Company will issue a release on Friday, November 6, at 12:00 p.m. ET / 5:00 p.m. UK time when the poster session starts.

Presentation details

Title: Phase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanoma (Abstract number: 1177)
Poster session: Poster Hall
Date and Time: Friday, November 6, 2026, 10:00 a.m. MST / 12:00 p.m. EST

Clinical oral abstract session: Session 2
Date and Time: Saturday, November 7, 2026, 1:45 p.m. MST / 3:45 p.m. EST

About ImmTAC**®** molecules for cancer

Immunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognize and kill cancer cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on demonstrated T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of mutational burden or immune infiltration, tumors that are characterized as immune “cold” or having low mutation burden.

About the IMC-F106C-101 Phase 1/2 trial

IMC-F106C-101 is a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumors, including non-small cell lung and ovarian cancers, as well as uveal melanoma, evaluating brenetafusp both as monotherapy and in combination arms with standards-of-care. The Phase 1 dose escalation portion of the trial was designed to determine the maximum tolerated dose (MTD), as well as to evaluate the safety, preliminary anti-tumor activity and pharmacokinetics of IMC-F106C (brenetafusp) both as monotherapy and in combination with standards-of-care. Brenetafusp is a bispecific protein built on Immunocore’s ImmTAC technology, and the Company’s first molecule to target the PRAME antigen.

About KIMMTRAK

KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.

IMPORTANT SAFETY INFORMATION

Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK, with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS.

Skin Reactions

Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.

Elevated Liver Enzymes

Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.

Embryo-Fetal Toxicity

KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last dose.

The most common adverse reactions (≥30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common (≥50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate.

October 15, 2026 7:00am EDT Download as PDF

Immunocore announces first patient dosed in the Phase 1 trial of

IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

The Phase 1 trial will assess the safety and clinical activity of IMC-S118AI in HLA-A*02:01-positive patients with type 1 diabetes

Preclinical data supporting unique mechanism of action recently published
in Science Advances

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 15 October 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that the first patient with type 1 diabetes (T1D) has been dosed in the Phase 1 trial (NCT07493122 ) of IMC-S118AI1.

IMC-S118AI, the Company’s first candidate for autoimmune diseases, is a novel bispecific molecule designed to down-modulate the immune system in a tissue-specific manner to protect beta cells under T cell attack in T1D. One end of the investigational bispecific therapy binds to a preproinsulin peptide presented by HLA-A*02:01 on beta cells to provide tissue-specificity, and the other end is a PD-1 agonist effector arm designed to turn off autoreactive T cells in order to help preserve insulin production and beta cell mass.

“This is a very exciting development for the type 1 diabetes community. We know that T1D is not a systemic autoimmune disease; it is exquisitely targeted to the insulin-making beta cells which comprise just 1% of the pancreas,” said Prof. Colin Dayan, Professor of Diabetes and Metabolism, Department of Immunology and Immunotherapy at the University of Birmingham. “In T1D, we need a high degree of safety for tissue-specific therapies to be chosen over insulin that we have used for over 100 years. This targeted immune therapy specific for beta cells, now in a Phase 1 trial could offer us an effective and well-tolerated treatment option, if supported by clinical data.”

“With our modular bispecific platform already validated in oncology and with initial proof of concept in infectious disease indications, we are now focused on evaluating this technology in a third therapeutic area. Our goal is to leverage a tissue-targeted approach to protect beta cells and preserve insulin secretion in patients,” said Dr. Mohammed Dar, Executive Vice President, Clinical Development and Chief Medical Officer of Immunocore.

In a recent _Science Advances_2 publication, Immunocore, in collaboration with the University of Florida, demonstrated in live human pancreas tissue slices, including from a recent-onset type 1 diabetes donor, that IMC-S118AI selectively binds to HLA-A*02:01-positive beta cells, and suppresses autoreactive T cell activity around islets, helping protect beta cells and preserve insulin secretion.

The Phase 1 dose escalation trial will evaluate the safety, pharmacokinetics and clinical activity of IMC-S118AI in HLA-A*02:01-positive type 1 diabetes patients.

About ImmTAAI**®** molecules and autoimmune diseases

ImmTAAI (Immune mobilizing monoclonal TCRs Against AutoImmune disease) molecules are novel bispecifics that are designed for tissue-specific down modulation of the immune system. When tethered to the tissue of interest, ImmTAAI candidates suppress autoreactive T cells via PD1 receptor agonism. The Company is enrolling people with type 1 diabetes in a Phase 1 trial and advancing a second candidate for inflammatory dermatological diseases.

About the IMC-S118AI Phase 1 trial

The trial is a first-in-human, Phase 1 dose escalation trial designed to evaluate the safety, pharmacokinetics and clinical activity of IMC-S118AI in HLA-A*02:01-positive patients with type 1 diabetes.

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including nine active clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the design, progress, timing, enrollment, scope, and results of the Phase 1 trial of IMC-S118AI; and the expected clinical benefits of IMC-S118AI. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company’s business, financial position, strategy and anticipated milestones, including Immunocore’s ability to conduct ongoing and planned clinical trials; Immunocore’s ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products; Immunocore’s ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore’s ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore’s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore’s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict in the Middle East, and global geopolitical tension; Immunocore’s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any of its product candidates it or its collaborators are developing; and the success of Immunocore’s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore’s filings with the Securities and Exchange Commission, including Immunocore’s most recent Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission on February 25, 2026, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law.

Prompts

Immunocore Holdings plc (ticker IMCR), listed in United States.

Company History

Date Change Detail
Dec 31, 2023 Reporting currency Its US reports are in USD instead of GBP from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

ETFs Holding Immunocore Holdings plc

ETF Weight in ETF Shares Market value As of
CANC 0.77% 44,900 $ 1.631M Aug 31, 2026
APIE 0.02% 5,043 $ 183.162K Aug 31, 2026